Literature DB >> 10400673

Arginine 336 and asparagine 333 of the human cholecystokinin-A receptor binding site interact with the penultimate aspartic acid and the C-terminal amide of cholecystokinin.

V Gigoux1, C Escrieut, J A Fehrentz, S Poirot, B Maigret, L Moroder, D Gully, J Martinez, N Vaysse, D Fourmy.   

Abstract

The cholecystokinin-A receptor (CCK-AR) is a G protein-coupled receptor that mediates important central and peripheral cholecystokinin actions. Residues of the CCK-AR binding site that interact with the C-terminal part of CCK that is endowed with biological activity are still unknown. Here we report on the identification of Arg-336 and Asn-333 of CCK-AR, which interact with the Asp-8 carboxylate and the C-terminal amide of CCK-9, respectively. Identification of the two amino acids was achieved by dynamics-based docking of CCK in a refined three-dimensional model of CCK-AR using, as constraints, previous results that demonstrated that Trp-39/Gln-40 and Met-195/Arg-197 interact with the N terminus and the sulfated tyrosine of CCK, respectively. Arg-336-Asp-8 and Asn-333-amide interactions were pharmacologically assessed by mutational exchange of Arg-336 and Asn-333 in the receptor or reciprocal elimination of the partner chemical functions in CCK. This study also allowed us to demonstrate that (i) the identified interactions are crucial for stabilizing the high affinity phospholipase C-coupled state of the CCK-AR.CCK complex, (ii) Arg-336 and Asn-333 are directly involved in interactions with nonpeptide antagonists SR-27,897 and L-364,718, and (iii) Arg-336 but not Asn-333 is directly involved in the binding of the peptide antagonist JMV 179 and the peptide partial agonist JMV 180. These data will be used to obtain an integrated dynamic view of the molecular processes that link agonist binding to receptor activation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10400673     DOI: 10.1074/jbc.274.29.20457

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  Pharmacological evidence for putative CCK(1) receptor heterogeneity in human colon smooth muscle.

Authors:  M F Morton; E A Harper; I A Tavares; N P Shankley
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

2.  Multiple post-translational modifications affect heterologous protein synthesis.

Authors:  Alexander A Tokmakov; Atsushi Kurotani; Tetsuo Takagi; Mitsutoshi Toyama; Mikako Shirouzu; Yasuo Fukami; Shigeyuki Yokoyama
Journal:  J Biol Chem       Date:  2012-06-06       Impact factor: 5.157

3.  Probing a model of a GPCR/ligand complex in an explicit membrane environment: the human cholecystokinin-1 receptor.

Authors:  Jérôme Hénin; Bernard Maigret; Mounir Tarek; Chantal Escrieut; Daniel Fourmy; Christophe Chipot
Journal:  Biophys J       Date:  2005-12-02       Impact factor: 4.033

Review 4.  Understanding Peptide Binding in Class A G Protein-Coupled Receptors.

Authors:  Irina G Tikhonova; Veronique Gigoux; Daniel Fourmy
Journal:  Mol Pharmacol       Date:  2019-07-10       Impact factor: 4.436

5.  The molecular basis for high affinity of a universal ligand for human bombesin receptor (BnR) family members.

Authors:  Hirotsugu Uehara; Simon J Hocart; Nieves González; Samuel A Mantey; Tomoo Nakagawa; Tatsuro Katsuno; David H Coy; Robert T Jensen
Journal:  Biochem Pharmacol       Date:  2012-07-22       Impact factor: 5.858

6.  Development of a highly selective allosteric antagonist radioligand for the type 1 cholecystokinin receptor and elucidation of its molecular basis of binding.

Authors:  Maoqing Dong; Ashton M Vattelana; Polo C-H Lam; Andrew J Orry; Ruben Abagyan; Arthur Christopoulos; Patrick M Sexton; David R Haines; Laurence J Miller
Journal:  Mol Pharmacol       Date:  2014-10-15       Impact factor: 4.436

7.  Exploring the binding pocket for pyridopyrimidine ligands at the CCK1 receptor by molecular docking.

Authors:  Amel Toumi-Maouche; Boubekeur Maouche; Safia Taïri-Kellou; Salima El-Aoufi; Mercedes Martín-Martínez; Rosario González-Muñiz; Daniel Fourmy; Bernard Maigret
Journal:  J Mol Model       Date:  2008-02-20       Impact factor: 1.810

8.  Molecular basis for high affinity and selectivity of peptide antagonist, Bantag-1, for the orphan BB3 receptor.

Authors:  Taichi Nakamura; Irene Ramos-Álvarez; Tatiana Iordanskaia; Paola Moreno; Samuel A Mantey; R T Jensen
Journal:  Biochem Pharmacol       Date:  2016-06-23       Impact factor: 5.858

9.  Use of multidimensional fluorescence resonance energy transfer to establish the orientation of cholecystokinin docked at the type A cholecystokinin receptor.

Authors:  Kaleeckal G Harikumar; Fan Gao; Delia I Pinon; Laurence J Miller
Journal:  Biochemistry       Date:  2008-08-13       Impact factor: 3.162

10.  Conserved cholecystokinin receptor transmembrane domain IV amino acids confer peptide affinity.

Authors:  Yong Ren; Michael Bläker; Lakshmi Seshadri; Edward W McBride; Martin Beinborn; Alan S Kopin
Journal:  J Mol Neurosci       Date:  2003-04       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.